Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,748,019
  • Shares Outstanding, K 192,709
  • Annual Sales, $ 221,900 K
  • Annual Income, $ -535,760 K
  • EBIT $ -610 M
  • EBITDA $ -604 M
  • 60-Month Beta 1.26
  • Price/Sales 66.35
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.06% (+0.58%)
  • Historical Volatility 30.62%
  • IV Percentile 52%
  • IV Rank 43.27%
  • IV High 77.11% on 08/05/25
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 21) 6.72 (8.86%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 239
  • Volume Avg (30-Day) 1,810
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 73,064
  • Open Int (30-Day) 79,089
  • Expected Range 69.09 to 82.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 9
  • High Estimate -0.57
  • Low Estimate -0.91
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +43.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.35 +7.75%
on 12/10/25
78.44 -3.37%
on 12/22/25
+4.08 (+5.69%)
since 11/26/25
3-Month
50.50 +50.10%
on 09/29/25
78.44 -3.37%
on 12/22/25
+25.75 (+51.45%)
since 09/26/25
52-Week
27.23 +178.37%
on 12/30/24
78.44 -3.37%
on 12/22/25
+47.41 (+167.00%)
since 12/26/24

Most Recent Stories

More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 75.80 (-0.95%)
This Hot Biotech Stock Just Set New All-Time Highs

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to...

BBIO : 75.80 (-0.95%)
Is Moderna Stock Underperforming the Nasdaq?

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

$NASX : 23,593.10 (-0.09%)
BBIO : 75.80 (-0.95%)
MRNA : 31.20 (-4.73%)
Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

With one blockbuster product, this biotech is gearing up for more product launches next year.

$SPX : 6,929.94 (-0.03%)
BBIO : 75.80 (-0.95%)
BridgeBio to Participate in December Investor Conferences

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 75.80 (-0.95%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 75.80 (-0.95%)
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared...

BBIO : 75.80 (-0.95%)
BridgeBio to Participate in November Investor Conferences

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 75.80 (-0.95%)
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 75.80 (-0.95%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 75.80 (-0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 78.05
2nd Resistance Point 77.69
1st Resistance Point 77.11
Last Price 75.80
1st Support Level 76.16
2nd Support Level 75.80
3rd Support Level 75.22

See More

52-Week High 78.44
Last Price 75.80
Fibonacci 61.8% 58.88
Fibonacci 50% 52.83
Fibonacci 38.2% 46.79
52-Week Low 27.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar